Vaccines protect against a large spectrum of infections. The eradication of deadly smallpox in the past and lately the declining statistics of polio are the most wonderful examples of the effect of the vaccine on humans. Here are some of the most promising vaccines on their way in 2018. Continue reading.. Total Word Counts: 1431
A most-up-to review of the past and current status of the Non-Alcoholic Steatohepatitis (NASH) drug discovery pipeline. Once thought to be the disease of obese, Non-Alcoholic Steatohepatitis (NASH) has generated enormous interest in biotech and pharma industries in the last few years. Why now and what they are doing? Read to follow all the updates on the NASH disease drug discovery updates from the Industry.
The liquid biopsy market is forecasted to grow at a CAGR of 20.6 percent in the next 10 years to reach over $3 billion from its current size of over $456 million. This review presents an illustration of how it works to help the new readers and also presents an account of all the industrial progress that was made in the last decade, indicating the key players in the global market. It also consists of a dedicated section discussing the current status of liquid biopsy test in India and a summary for the Indian companies working on it. Note: This is a Medgenera Exclusive Review and you need to subscribe to access the full article.
The global oncology mAb market is expected to reach around $45 billion by the end of this decade, and many big drugs will lose patent protection during this time. This makes immunology and oncology biosimilars a perfect space to enter for companies. Furthermore, blockbuster drugs worth about $60 billion will go-off-patent in the US alone. This would push the current global biosimilar market of $2 billion to around $12 billion by 2020. Are you prepared to delve into this booming industry that holds high growth prospects? Read the article to get more insights about the biosimilars industry trends and future forecasts.